Home | Pharmaceutical Outsourcing - The Journal of Pharmaceutical & Biopharmaceutical Contract Services

Close Ad ☒

Show Ad

Flexibility as a Core IND Strategy
With the increasing complexities of current IND programs, it is critical to work with regulatory agencies to seek input early in the process. read more
The Next Test for AI in Pharmacovigilance Is Trust, Not Accuracy
An AI model can be right and still not be trusted. That’s what Bristol Myers Squibb (BMS) found six months into rolling out AI-powered adverse event processing: while F1 performance scores were tracking upward, the audit trail found reviewers still reopening cases the system had already cleared. read more
An Interview With Dave Miller, Ph.D.
Early formulation decisions can make or break a program, yet they’re often made under significant data constraints. What are the most common mistakes sponsors make when they rush that decision, and what does it typically cost them downstream? read more
Building Resilient Pharma Supply Chains to Strengthen Patient Healthcare
Continuity of care is generally defined in terms of a patient’s ongoing contact with a clinical team and how smoothly their care progresses between providers. Often overlooked is the pharma supply chain and its role in ensuring this continuity. read more

Clinical Trials - Transforming Drug Development
Transforming Drug Development: Accelerating Clinical Trials through Patient-Centric Innovations and Technological Breakthroughs Watch Now

Cambrex Breaks Ground on $120M Charles City Expansion
Thursday, November 05, 2026
Cambrex has broken ground on a $120 million expansion at its Charles City, Iowa facility. The project will add 160,000 liters of manufacturing ... read more
Alcami Promotes Robert Tragas to VP, Laboratory Services
Thursday, November 05, 2026
Alcami has promoted Robert Tragas to Vice President, Laboratory Services. In his expanded role, Tragas will lead laboratory operations across the CDMO... read more
Samsung Biologics Earns 'Negligible Risk' ESG Rating
Thursday, November 05, 2026
Samsung Biologics has achieved a 'Negligible Risk' rating in the latest Morningstar Sustainalytics ESG Risk Ratings assessment. The CDMO received an ... read more
Pyramid Pharma Services Adds 13th Commercial Product
Thursday, November 05, 2026
Pyramid Pharma Services has expanded a partnership with a longstanding biopharmaceutical customer to manufacture its 13th commercial product: a ... read more
Lonza to Acquire Merck KGaA's US CDMO Sites
Tuesday, November 03, 2026
Lonza has signed a definitive agreement to acquire five CDMO manufacturing sites in the US from Merck KGaA, Darmstadt, Germany, at a total enterprise ... read more